- €21.69m
- €19.48m
- €25.74m
- 35
- 64
- 14
- 28
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.08 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -4% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.56 | ||
| Price to Tang. Book | 1.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.76 | ||
| EV to EBITDA | 11.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.03% | ||
| Return on Equity | -57.22% | ||
| Operating Margin | 3.62% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 21.11 | 31.27 | 30.35 | 28.79 | 25.74 | 34.1 | 41.8 | 16.44% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | -4 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Directors
- Ulrich Granzer CSU (60)
- Hermann Luebbert CMG (65)
- Juergen Baumann VSU (67)
- Ludwig Lutter CFO
- John Borer SUB (63)
- Reinhard Eyring SUB (62)
- Franca Ruhwedel SUB (48)
- Kevin Weber SUB (63)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- November 16th, 2000
- Public Since
- October 30th, 2006
- No. of Employees
- 91
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
XETRA- Shares in Issue
- 63,807,058
- Address
- Hemmelrather Weg 201, LEVERKUSEN, 51377
- Web
- https://biofrontera.com/
- Phone
- +49 null214876320
- Contact
- Tirth Patel
- Auditors
- Warth & Klein Grant Thornton AG
Latest News for B8F
Upcoming Events for B8F
Full Year 2023 Biofrontera AG Earnings Release
Q1 2024 Biofrontera AG Earnings Release
Biofrontera AG Annual Shareholders Meeting
Q2 2024 Biofrontera AG Earnings Release
Similar to B8F
FAQ
As of Today at 19:04 UTC, shares in Biofrontera AG are trading at €0.34. This share price information is delayed by 15 minutes.
Shares in Biofrontera AG last closed at €0.34 and the price had moved by -69.78% over the past 365 days. In terms of relative price strength the Biofrontera AG share price has underperformed the FTSE Global All Cap Index by -72.12% over the past year.
The overall consensus recommendation for Biofrontera AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Biofrontera AG does not currently pay a dividend.
Biofrontera AG does not currently pay a dividend.
Biofrontera AG does not currently pay a dividend.
To buy shares in Biofrontera AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.34, shares in Biofrontera AG had a market capitalisation of €21.69m.
Here are the trading details for Biofrontera AG:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: B8F
Based on an overall assessment of its quality, value and momentum Biofrontera AG is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biofrontera AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -46.72%.
As of the last closing price of €0.34, shares in Biofrontera AG were trading -34.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biofrontera AG PE ratio based on its reported earnings over the past 12 months is 7.08. The shares last closed at €0.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biofrontera AG's management team is headed by:
- Ulrich Granzer - CSU
- Hermann Luebbert - CMG
- Juergen Baumann - VSU
- Ludwig Lutter - CFO
- John Borer - SUB
- Reinhard Eyring - SUB
- Franca Ruhwedel - SUB
- Kevin Weber - SUB